Development of a trivalent T-cell product containing CAR molecules targeting HER2, IL13Rα2, and EphA2, helped overcome interpatient antigenic variability glioblastoma sample cohort.93 Clinical trial (NCT05168423) developed a bivalent CAR T cell targeting both EGFR and IL13Rα2.94,95 Early results showed minimal neurotoxicity at two doses of CART-EGFR-IL13Rα2 cells, with limited cases of iCANS.94 Here, EGFR is linked to glioblastoma.